Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 21Parkinson Disease 4, Autosomal Dominant Lewy Body 5Kidney Neoplasms 5von Hippel-Lindau Disease 4Pheochromocytoma 2Paraganglioma 2Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Metastatic Castration-Resistant Prostate Cancer 1Hemangioblastoma 1Glioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 34Cisplatin 30Brachytherapy 16Paclitaxel 15Carboplatin 15Bevacizumab 15Radiotherapy 14Blood Specimen Collection 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Colposcopy 11Nivolumab 10Drug Therapy 10atezolizumab 8Human Papillomavirus DNA Tests 8Gemcitabine 8lenvatinib 7Radiation 6Platinum 6Biopsy 6toripalimab 5cemiplimab 5Surveys and Questionnaires 5Standard of Care 5Radiotherapy, Intensity-Modulated 5Practice Guidelines as Topic 5Patient Navigation 5Methods 5Fulvestrant 5Fluorodeoxyglucose F18 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × belzutifan × 1 year × Clear all
NCT06677190 2025-11-05

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡